When tested on real biological samples, the immunosensor detected an average abnormal serum HER2 level of 34 ng/mL in invasive breast cancer patients, while healthy individuals and non-invasive breast cancer patients showed an average level of 13.45 ng/mL. This evidence concerns the gene ERBB2 and breast carcinoma.